Safety and efficacy of protease inhibitor based combination therapy in a single-center " real-life" cohort of 110 patients with chronic hepatitis C genotype 1 infection

BMC Gastroenterology

Volumn 14, Issue 1, 2014, Pages

  Wehmeyer, Malte H ^a   Eißing, Friederike ^a   Jordan, Sabine ^a   Röder, Claudia ^a   Hennigs, Annette ^a   Degen, Olaf ^a   Hüfner, Anja ^a   Hertling, Sandra ^a   Schmiedel, Stefan ^a   Sterneck, Martina ^a   van Lunzen, Jan ^a   Lohse, Ansgar W ^a   Zur Wiesch, Julian S ^a   Lüth, Stefan ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Boceprevir; SAE; Serious adverse events; Side effects; Sustained virological response; SVR; Telaprevir

Indexed keywords

ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BOCEPREVIR; PROTEINASE INHIBITOR; TELAPREVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-(2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-3-AZABICYCLO(3.1.0)HEXAN-2-CARBOXAMIDE; OLIGOPEPTIDE; PROLINE; RIBAVIRIN;

ADVERSE OUTCOME; ANEMIA; ANORECTAL DISEASE; ARTICLE; AUTOIMMUNE DISEASE; COHORT ANALYSIS; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; DYSGEUSIA; FATIGUE; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL DISEASE; GENOTYPE; HEART DISEASE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ILEUS; INFECTION; INSOMNIA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; LIVER TRANSPLANTATION; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MENTAL DISEASE; MIXED INFECTION; MORTALITY; NEUROLOGIC DISEASE; NEUTROPENIA; RASH; THROMBOCYTE COUNT; THROMBOCYTOPENIA; ANALOGS AND DERIVATIVES; DRUG COMBINATION; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; TREATMENT OUTCOME; VIRUS LOAD;

ANTIVIRAL AGENTS; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; PROLINE; PROTEASE INHIBITORS; RIBAVIRIN; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84900011345     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-14-87     Document Type: Article

References (20)

1. Global surveillance and control of hepatitis C: report of a WHO consultation organized in collaboration with the viral hepatitis prevention board, Antwerp, Belgium. J Viral Hepat 1999, 6:35-47.
2. Amin J, Law MG, Bartlett M, Kaldor JM, Dore GJ. Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study. Lancet 2006, 368:938-945. 10.1016/S0140-6736(06)69374-4, 16962883.
3. Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DuNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP. Boceprevir for untreated chronic HCV genotype 1-infection. N Engl J Med 2011, 364:1195-206. 10.1056/NEJMoa1010494, 3766849, 21449783.
4. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011, 364:2405-16. 10.1056/NEJMoa1012912, 21696307.
5. Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, Fried MW, Adler M, Reesink HW, Martin M, Sankoh AJ, Adda N, Kauffman RS, George S, Wright CI, Poordad F. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011, 365:1014-24. 10.1056/NEJMoa1014463, 3809077, 21916639.
6. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011, 364:1207-17. 10.1056/NEJMoa1009482, 3153125, 21449784.
7. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Müllhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M. Telaprevir for retreatment of HCV infection. N Engl J Med 2011, 364:2417-28. 10.1056/NEJMoa1013086, 21696308.
8. Backus LI, Belperio PS, Shahoumian TA, Cheung R, Mole LA. Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort. Aliment Pharmacol Ther 2014, 39:93-103. 10.1111/apt.12546, 24206566.
9. Maasoumy B, Port K, Markova AA, Serrano BC, Rogalska-Taranta M, Sollik L, Mix C, Kirschner J, Manns MP, Wedemeyer H, Cornberg M. Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting. PLoS ONE 8(2):e55285. doi:10.1371/journal.pone.0055285.
10. Hézode C, Fontaine H, Dorival C, Larrey D, Zoulim F, Canva V, de Ledinghen V, Poynard T, Samuel D, Bourlière M, Zarski JP, Raabe JJ, Alric L, Marcellin P, Riachi G, Bernard PH, Loustaud-Ratti V, Métivier S, Tran A, Serfaty L, Abergel A, Causse X, Di Martino V, Guyader D, Lucidarme D, Grando-Lemaire V, Hillon P, Feray C, Dao T, Cacoub P, et al. Triple therapy in treatment-experienced patients with hcv-cirrhosis in a multicentre cohort from the french early access programme (anrs co20-CUPIC) - NCT01514890. J Hepatol 2013, 59:434-441. 10.1016/j.jhep.2013.04.035, 23669289.
11. Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 2008, 48:835-47. 10.1016/j.jhep.2008.02.008, 18334275.
12. Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973, 60:646-9. 10.1002/bjs.1800600817, 4541913.
13. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, D'Amico G, Dickson ER, Kim WR. A model to predict survival in patients with end-stage liver disease. Hepatology 2001, 33:464-70. 10.1053/jhep.2001.22172, 11172350.
14. Fried MW, Hadziyannis SJ, Shiffman ML, Messinger D, Zeuzem S. Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. J Hepatol 2011, 55:69-75. 10.1016/j.jhep.2010.10.032, 21145856.
15. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American association for the study of liver diseases. Hepatology 2011, 54:1433-44. 10.1002/hep.24641, 3229841, 21898493.
16. Sarrazin C, Berg T, Cornberg M, Dollinger M, Ferenci P, Hinrichsen H, Klinker H, Kraus M, Manns M, Mauss S, Peck-Radosavljevic M, Schmidt H, Spengler U, Wedemeyer H, Wirth S, Zeuzem S. Expert opinion on boceprevir- and telaprevir-based triple therapies of chronic hepatitis C. Z Gastroenterol 2012, 50:57-72.
17. Schulze zur Wiesch J, Pudelski N, Hoepner L, Supplieth M, Buggisch P, Lohse AW, Lüth S. " Real-life" comparison of pegylated-interferon 2a versus 2b combination therapy of chronic hepatitis c virus. Hepatology 2011, 53:1405-1406. 10.1002/hep.24233, 21480360.
18. Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, Urban T, Afdhal NH, Jacobson IM, Esteban R, Poordad F, Lawitz EJ, McCone J, Shiffman ML, Galler GW, Lee WM, Reindollar R, King JW, Kwo PY, Ghalib RH, Freilich B, Nyberg LM, Zeuzem S, Poynard T, Vock DM, Pieper KS, Patel K, Tillmann HL, Noviello S, Koury K, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virological response in genotype 1 hepatitis C virus. Gastroenterology 2010, 139:120-129. 10.1053/j.gastro.2010.04.013, 20399780.
19. Pol S, Aerssens J, Zeuzem F, Andreone P, Lawitz EJ, Roberts S, Younossi Z, Foster GR, Focaccia R, Horban A, Pockros PJ, Van Heeswijk RP, De Meyer S, Luo D, Botfield M, Beumont M, Picchio G. Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure. J Hepatol 2013, 58:883-889. 10.1016/j.jhep.2012.12.023, 23321318.
20. Poordad F, Bronowicki JP, Gordon SC, Zeuzem S, Jacobson IM, Sulkowski MS, Poynard T, Morgan TR, Molony C, Pedicone LD, Sings HL, Burroughs MH, Sniukiene V, Boparai N, Goteti VS, Brass CA, Albrecht JK, Bacon BR. Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology 2012, 143:608-618. 10.1053/j.gastro.2012.05.011, 22626609.